Literature DB >> 28670498

Application of AFP whole blood one-step rapid detection kit in screening for HCC in Qidong.

Jie Jin1, Xiao-Yan Zhang2, Jin-Lei Shi1, Xue-Feng Xue3, Ling-Ling Lu3, Jian-Hua Lu3, Xiao-Ping Jiang3, Jiang-Feng Hu4, Ben-Song Duan4, Chang-Qing Yang4, Da-Ru Lu2, De-Li Lu5, Jian-Guo Chen3, Heng-Jun Gao1,4.   

Abstract

Hepatocellular carcinoma (HCC) is a big problem in China where the Hepatitis B (HBV) infection patients are near to 120 million. Early screening and diagnosis is the key to reduce the incidence and mortality of HCC. Serum AFP detection is the main methods for diagnosis, recurrent monitoring and therapeutic evaluation of primary HCC. Hepatitis patients should detect the AFP at least once every six months to help early diagnosis of HCC. Unfortunately, most hepatitis and other liver disease patients do not test their AFP regularly. Therefore, a rapid, convenient detect kit for AFP is necessary for the hepatitis patients to test AFP at home by themselves. It will be very helpful to the HCC early screening and early diagnosis. We screened 859 individuals who were HBsAg positive and had high risk of HCC in Qidong by using two different kits, AFP one-step rapid detection kit (Shanghai Outdo Biotech) and AFP Diagnostics ELISA kit (Zhengzhou Autobio Diagnostics), and compared the results. As a result, the positive accordance rate and the negative accordance rate of AFP one-step rapid detection kit and the Autobio ELISA kit were 95.65% (22/23) and 99.40% (831/836), respectively. The total diagnose accordance rate reached up to 99.30% (853/859). The screening results showed a high accordance rate of two methods. It is so meaningful to achieve home-test and improve HCC early screening and diagnosis by using AFP one-step rapid detection kit.

Entities:  

Keywords:  AFP; HCC; accordance rate; early diagnosis; whole blood one-step rapid detection

Year:  2017        PMID: 28670498      PMCID: PMC5489785     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  8 in total

1.  [Long-term survival trends for liver cancer in Qidong: 1972 to 2011].

Authors:  Hairong Yao; Hao Chen; Jianguo Chen; Jian Zhu; Yonghui Zhang
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2014-12

2.  [Analysis of liver cancer mortality in the national retrospective sampling survey of death causes in China, 2004 - 2005].

Authors:  Jian-guo Chen; Si-wei Zhang; Wan-qing Chen
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  2010-05

Review 3.  Liver cancer epidemic in China: past, present and future.

Authors:  Jian Guo Chen; Si Wei Zhang
Journal:  Semin Cancer Biol       Date:  2010-12-07       Impact factor: 15.707

4.  [Significance of prospective follow-up cohort study in diagnosis and treatment of primary hepatic cancer among HBsAg carriers].

Authors:  P Lu; J Wang; Y Wu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2001-07-25

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  Screening for liver cancer: results of a randomised controlled trial in Qidong, China.

Authors:  J-G Chen; D M Parkin; Q-G Chen; J-H Lu; Q-J Shen; B-C Zhang; Y-R Zhu
Journal:  J Med Screen       Date:  2003       Impact factor: 2.136

7.  TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China.

Authors:  Katarzyna Szymañska; Jian-Guo Chen; Yan Cui; Yun Yun Gong; Paul Craig Turner; Stéphanie Villar; Christopher Paul Wild; Donald Maxwell Parkin; Pierre Hainaut
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-14       Impact factor: 4.254

8.  Acceleration to death from liver cancer in people with hepatitis B viral mutations detected in plasma by mass spectrometry.

Authors:  Jian Guo Chen; Shuang Yuan Kuang; Patricia A Egner; Jian Hua Lu; Yuan Rong Zhu; Jin Bing Wang; Bao Chu Zhang; Tao Yang Chen; Alvaro Muñoz; Thomas W Kensler; John D Groopman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

  8 in total
  4 in total

1.  lncRNA Expression-Based Risk Scoring System Can Predict Survival of Tumor-Positive Patients with Hepatocellular Carcinoma.

Authors:  Siyao Wu; Yayan Deng; Yue Luo; Jiaxiang Ye; Zhihui Liu
Journal:  Asian Pac J Cancer Prev       Date:  2021-12-01

2.  High nuclear expression of APE1 correlates with unfavorable prognosis and promotes tumor growth in hepatocellular carcinoma.

Authors:  Xiaohua Lu; Hui Zhao; Hongxin Yuan; Yushan Chu; Xiaoqing Zhu
Journal:  J Mol Histol       Date:  2021-01-04       Impact factor: 2.611

3.  Retinal dehydrogenase 5 (RHD5) attenuates metastasis via regulating HIPPO/YAP signaling pathway in Hepatocellular Carcinoma.

Authors:  Hao Hu; Liang Xu; Shao-Ju Luo; Ting Xiang; Yan Chen; Zhi-Rui Cao; Yu-Jian Zhang; Zhuomao Mo; Yongdan Wang; Dong-Fang Meng; Ling Yu; Li-Zhu Lin; Shi-Jun Zhang
Journal:  Int J Med Sci       Date:  2020-07-19       Impact factor: 3.738

Review 4.  Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know.

Authors:  Jacek Baj; Łukasz Bryliński; Filip Woliński; Michał Granat; Katarzyna Kostelecka; Piotr Duda; Jolanta Flieger; Grzegorz Teresiński; Grzegorz Buszewicz; Marzena Furtak-Niczyporuk; Piero Portincasa
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.